1 – 20 of 20
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
(
- Contribution to journal › Article
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
- 2022
-
Mark
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
(
- Contribution to journal › Article
- 2021
-
Mark
Epidemiology and Etiology of AML
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Acute myeloid leukemia in patients we judge as being older and/or unfit
(
- Contribution to journal › Scientific review
-
Mark
Impact of treatment delay in acute myeloid leukemia revisited
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article
-
Mark
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
(
- Contribution to journal › Article
-
Mark
Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia
2021) In International Journal of Laboratory Hematology(
- Contribution to journal › Article
- 2020
-
Mark
Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis
(
- Contribution to journal › Article
-
Mark
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014 : improving performance status is a major contributing factor
(
- Contribution to journal › Letter
-
Mark
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years
(
- Contribution to journal › Letter
-
Mark
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
(
- Contribution to journal › Article
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
(
- Contribution to journal › Article
- 2017
-
Mark
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells
(
- Contribution to journal › Article
- 2012
-
Mark
Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
(
- Contribution to journal › Article
-
Mark
Acute myeloid leukemia in the real world: why population-based registries are needed.
(
- Contribution to journal › Article
- 2011
-
Mark
Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder
(
- Contribution to journal › Article
-
Mark
Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006.
(
- Contribution to journal › Article